Sandra Beaver Sells 8,996 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at $2,301,710.58. This trade represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total value of $17,208.10.

Evolus Stock Down 0.2 %

EOLS stock traded down $0.03 during mid-day trading on Monday, reaching $13.00. The company had a trading volume of 527,427 shares, compared to its average volume of 591,935. Evolus, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The company has a market capitalization of $826.63 million, a price-to-earnings ratio of -14.29 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a fifty day simple moving average of $13.42 and a 200 day simple moving average of $13.87.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EOLS. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th.

Remove Ads

Institutional Investors Weigh In On Evolus

Large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Evolus by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company's stock valued at $347,000 after buying an additional 1,094 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Evolus by 2.2% in the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock valued at $885,000 after acquiring an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC raised its position in shares of Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock worth $378,000 after purchasing an additional 2,044 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.